Specific small molecule inhibitors of Skp2-mediated p27 degradation.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Chemistry and Biology

• Publication date

  2012-12-21

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.chembiol.2012.09.015PMID 23261596PMCID PMC3530153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.

  2011cited by this paper
• An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.

  2011cited by this paper
• WW Domain-containing E3 Ubiquitin Protein Ligase 1 (WWP1) Delays Cellular Senescence by Promoting p27Kip1 Degradation in Human Diploid Fibroblasts*

  2011cited by this paper
• Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice

  2010cited by this paper
• Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention.

  2010cited by this paper
• Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

  2010cited by this paper
• Structural Determinants of PERK Inhibitor Potency and Selectivity

  2010cited by this paper
• Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence

  2010cited by this paper
• Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells

  2010cited by this paper
• An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase

  2010cited by this paper
• Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase.

  2010cited by this paper
• An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

  2009cited by this paper
• Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.

  2008cited by this paper
• Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.

  2008influential reference
• Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

  2008cited by this paper
• Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer

  2008cited by this paper
• The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

  2008cited by this paper
• Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

  2008cited by this paper
• Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer

  2008cited by this paper
• Knockdown of S-phase kinase-associated protein-2 expression in MCF-7 inhibits cell growth and enhances the cytotoxic effects of epirubicin.

  2007cited by this paper
• Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes

  2007cited by this paper
• Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.

  2007cited by this paper
• Bortezomib for the Treatment of Mantle Cell Lymphoma

  2007cited by this paper
• Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi

  2006cited by this paper
• Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo.

  2006cited by this paper
• E3 ubiquitin ligases as cancer targets and biomarkers.

  2006cited by this paper
• S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth.

  2006cited by this paper
• Ubiquitin ligases: cell-cycle control and cancer

  2006cited by this paper
• S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth

  2006cited by this paper
• Ubiquitination of p27Kip1 Requires Physical Interaction with Cyclin E and Probable Phosphate Recognition by SKP2*

  2005influential reference
• Proteolysis: from the lysosome to ubiquitin and the proteasome

  2005cited by this paper
• Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase.

  2005cited by this paper
• Function and regulation of cullin–RING ubiquitin ligases

  2005cited by this paper
• Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells.

  2005cited by this paper
• Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome.

  2005cited by this paper
• Structural Basis of the Cks 1-Dependent Recognition of p 27 Kip 1 by the SCFSkp 2 Ubiquitin Ligase

  2005cited by this paper
• Druggability of SCF ubiquitin ligase-protein interfaces.

  2005cited by this paper
• Cellular, Biochemical, and Genetic Analysis of Mechanism of Small Molecule IAP Inhibitors*

  2004cited by this paper
• Molecular and Biochemical Characterization of the Skp2-Cks1 Binding Interface*

  2004cited by this paper
• Comprehensive identification of "druggable" protein ligand binding sites.

  2004cited by this paper
• The SCF ubiquitin ligase: insights into a molecular machine

  2004cited by this paper
• Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27Kip1 at G1 phase

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

  2004cited by this paper
• Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship *

  2004cited by this paper
• Skp2-mediated degradation of p27 regulates progression into mitosis.

  2004cited by this paper
• Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis.

  2004cited by this paper
• Deregulated degradation of the cdk inhibitor p27 and malignant transformation.

  2003cited by this paper
• Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase*

  2003cited by this paper
• Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation

  2003cited by this paper
• A Negatively Charged Amino Acid in Skp2 Is Required for Skp2-Cks1 Interaction and Ubiquitination of p27Kip1*

  2003cited by this paper
• The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells

  2002cited by this paper
• Three Different Binding Sites of Cks1 Are Required for p27-Ubiquitin Ligation*

  2002cited by this paper
• High-throughput docking for lead generation.

  2001cited by this paper
• The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27

  2001cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27.

  1999cited by this paper
• Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.

  1999cited by this paper
• SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

  1999cited by this paper
• Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.

  1998cited by this paper
• Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins.

  1998cited by this paper
• Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

  1997cited by this paper
• F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex.

  1997cited by this paper
• ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation

  1994cited by this paper
• Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins.

  1994cited by this paper

• Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation.

  2026cites this paper
• The Establishment of Prostate-specific, SKP2 Humanized Mice by CRISPR Knock-in Method Reveals Neoplastic Initiation and Microenvironmental Reprogramming

  2026cites this paper
• Microtubule dynamics is a therapeutic vulnerability in VHL-deficient renal cell carcinoma

  2025cites this paper
• Molecular glue degrader function of SPOP inhibitors enhances STING-dependent immunotherapy efficacy in melanoma models

  2025cites this paper
• The multifaceted role of E3 ubiquitin ligases in cancer metastasis: mechanisms, targets, and therapeutic implications

  2025cites this paper
• SKP2 E3 ligase in urological malignancies: a critical regulator of the cell cycle and therapeutic target

  2025influential citation
• The cyclin-dependent kinase inhibitor p27 facilitates chemosensitivity by promoting ferroptosis in epithelial ovarian cancer

  2025cites this paper
• Targeting the Skp2-Cks1 protein-protein interaction: structures, assays, and preclinical inhibitors.

  2025cites this paper
• The Establishment of Prostate-specific, SKP2 Humanized Mice by CRISPR Knock-in Method Reveals Neoplastic Initiation and Microenvironmental Reprogramming

  2025cites this paper
• A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins

  2025cites this paper
• Targeting of SKP2 to combat drug resistance in multiple myeloma

  2025cites this paper
• A pan-cancer analysis revealed SKP2 as an inhibitor of the tumor immune microenvironment and a promising therapeutic target for immunotherapy.

  2025cites this paper
• A small-molecule degron with a phenylpropionic acid scaffold.

  2024cites this paper
• The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer

  2024cites this paper
• A patent review of SCF E3 ligases inhibitors for cancer：Structural design, pharmacological activities and structure-activity relationship.

  2024cites this paper
• What are the essential determinants of human papillomavirus carcinogenesis?

  2024cites this paper
• F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects

  2024cites this paper
• A framework for target discovery in rare cancers

  2024cites this paper
• SKping cell cycle regulation: role of ubiquitin ligase SKP2 in hematological malignancies

  2024cites this paper
• Exploring Ubiquitin-specific proteases as therapeutic targets in Glioblastoma.

  2024cites this paper
• Clinical potential of SKP2 as diagnostic marker and therapeutic target in small cell lung cancer.

  2024cites this paper
• Drug Discovery Approaches to Target E3 Ligases

  2024cites this paper
• Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

  2024cites this paper
• NSC689857, an inhibitor of Skp2, produces antidepressant-like effects in mice

  2024cites this paper
• A Critical Role of Endothelial Skp2/PTEN Axis in Angiogenesis and Psoriasis.

  2023cites this paper
• SKP2 knockout in Rb1/p53 deficient mouse models of osteosarcoma induces immune infiltration and drives a transcriptional program with a favorable prognosis.

  2023cites this paper
• Promoter methylation and enhanced SKP2 are associated with the downregulation of CDKN1C in cervical squamous cell carcinoma.

  2023cites this paper
• Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma

  2023cites this paper
• SKP2 knockout in Rb1/p53 deficient mouse models of osteosarcoma induces immune infiltration and drives a transcriptional program with a favorable prognosis

  2023cites this paper
• The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

  2023cites this paper
• Ceftazidime reduces cellular Skp2 to promote type‐I interferon activity

  2023cites this paper
• Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy

  2023cites this paper
• Targeted pharmacologic inhibition of S-phase kinase-associated protein 2 (SKP2) mediated cell cycle regulation in lung and other RB-Related cancers: A brief review of current status and future prospects.

  2023cites this paper
• Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer

  2023cites this paper
• Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review

  2023cites this paper
• Role of F-box proteins in human upper gastrointestinal tumors.

  2023cites this paper
• Somatic gain-of-function mutations in BUD13 promote oncogenesis by disrupting Fbw7 function

  2023cites this paper
• Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides

  2023cites this paper
• Molecular targets and therapeutic strategies for triple-negative breast cancer

  2023cites this paper
• E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities.

  2023cites this paper
• MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting

  2023cites this paper
• Inhibitors Targeting the F-BOX Proteins

  2023cites this paper
• Tyrphostin AG1024 Suppresses Coronaviral Replication by Downregulating JAK1 via an IR/IGF-1R Independent Proteolysis Mediated by Ndfip1/2_NEDD4-like E3 Ligase Itch

  2022cites this paper
• The roles of E3 ligases in Hepatocellular carcinoma.

  2022cites this paper
• SCF-SKP2 E3 ubiquitin ligase links mTORC1/ER stress/ISR with YAP activation in murine renal cystogenesis

  2022cites this paper
• Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2

  2022cites this paper
• CKS1 inhibition reveals vulnerabilities in leukemic stem cells with concomitant protection of healthy hematopoietic stem cells

  2022cites this paper
• Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition

  2022cites this paper
• Anti-tumor Effects of Skp2 Inhibitor AAA-237 on NSCLC by Arresting Cell Cycle at G0/G1 Phase and Inducing Senescence.

  2022cites this paper
• miR-590-5p Targets Skp2 to Inhibit the Growth and Invasion of Malignant Melanoma Cells

  2022cites this paper
• A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer

  2022cites this paper
• Functional roles of E3 ubiquitin ligases in prostate cancer

  2022cites this paper
• Design and synthesis of a DNA-encoded combinatorial library of bicyclic peptoids.

  2021cites this paper
• E3 ubiquitin ligases: styles, structures and functions

  2021cites this paper
• Ubiquitination Regulators Discovered by Virtual Screening for the Treatment of Cancer

  2021cites this paper
• Tilting MYC toward cancer cell death.

  2021cites this paper
• Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

  2021cites this paper
• Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy

  2021cites this paper
• Establishment of high-throughput screening HTRF assay for identification small molecule inhibitors of Skp2-Cks1

  2021cites this paper
• Estimation of Autophagy Activity By Evaluating Possible MicroRNA Biomarkers and FOXO1 mRNA Level in Papillary Thyroid Carcinoma

  2021cites this paper
• Cytosolic DNA sensing by cGAS: regulation, function, and human diseases

  2021cites this paper
• Ubiquitin ligases in cancer: functions and clinical potentials.

  2021cites this paper
• Emerging Roles of SKP2 in Cancer Drug Resistance

  2021cites this paper
• The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma

  2021cites this paper
• The Roles of Post-Translational Modifications on mTOR Signaling

  2021cites this paper
• The role of the ubiquitin proteasome system in glioma: analysis emphasizing the main molecular players and therapeutic strategies identified in glioblastoma multiforme.

  2021cites this paper
• Phytochemical library screening reveals betulinic acid as a novel Skp2‐SCF E3 ligase inhibitor in non–small cell lung cancer

  2021cites this paper
• Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges

  2021cites this paper
• The FBXW7‐NOTCH interactome: A ubiquitin proteasomal system‐induced crosstalk modulating oncogenic transformation in human tissues

  2021cites this paper
• [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].

  2020cites this paper
• Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle

  2020influential citation
• Targeting E3 Ubiquitin Ligases and Deubiquitinases in Ciliopathy and Cancer

  2020cites this paper
• The application of ubiquitin ligases in the PROTAC drug design.

  2020cites this paper
• Targeted modulation of E3 ligases using engineered ubiquitin variants

  2020cites this paper
• Skp2 in the ubiquitin-proteasome system: A comprehensive review.

  2020cites this paper
• Ubiquitin–proteasome system-targeted therapy for uveal melanoma: what is the evidence?

  2020cites this paper
• The Skp2 Pathway: A Critical Target for Cancer Therapy.

  2020cites this paper
• Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs.

  2020cites this paper
• F-box proteins and cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects

  2020cites this paper
• Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases.

  2020cites this paper
• Ubiquitin–proteasome system-targeted therapy for uveal melanoma: what is the evidence?

  2020cites this paper
• Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival

  2020cites this paper
• Targeting SCF E3 Ligases for Cancer Therapies.

  2020cites this paper
• Up‐regulation of cofilin‐1 in cell senescence associates with morphological change and p27kip1‐mediated growth delay

  2020cites this paper
• Quadruple-negative breast cancer: novel implications for a new disease

  2020cites this paper
• Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer

  2020influential citation
• Targeting the Ubiquitin System in Glioblastoma

  2020cites this paper
• Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis

  2019influential citation
• Ubiquitin Signaling in Regulation of the Start of the Cell Cycle

  2019cites this paper
• The Role of Ubiquitination in Regulating Embryonic Stem Cell Maintenance and Cancer Development

  2019cites this paper
• CD74 knockout attenuates alcohol intake-induced cardiac dysfunction through AMPK-Skp2-mediated regulation of autophagy.

  2019cites this paper
• Identification and structural characterization of deleterious non-synonymous single nucleotide polymorphisms in the human SKP2 gene

  2019cites this paper
• Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma.

  2019cites this paper
• E3 Ubiquitin Ligases in Cancer and Their Pharmacological Targeting

  2019cites this paper
• Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.

  2019cites this paper
• SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection

  2019cites this paper
• Effects of RNAi-induced Skp2 inhibition on cell cycle, apoptosis and proliferation of endometrial carcinoma cells

  2019influential citation
• SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27

  2019influential citation
• Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system

  2019cites this paper
• Roles of Ubiquitination and SUMOylation in DNA Damage Response.

  2019cites this paper